We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
-4.98%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.46B
AUM Growth
-$155M
Cap. Flow
+$105M
Cap. Flow %
3.02%
Top 10 Hldgs %
66.74%
Holding
34
New
4
Increased
12
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$40.4M
2
ESPR
Esperion Therapeutics
ESPR
+$38.9M
3
TSRO
TESARO, Inc.
TSRO
+$38.7M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$23.2M
5
EXEL icon
Exelixis
EXEL
+$21.9M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$49.8M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$29.4M
3
GILD icon
Gilead Sciences
GILD
+$21.2M
4
PRTA icon
Prothena Corp
PRTA
+$14.7M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
26
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$23.8M 0.69%
+480,000
New +$23.2M
EXEL icon
27
Exelixis
EXEL
$13.4B
$22.8M 0.66%
+1,060,000
New +$21.9M
FPRX
28
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$15.5M 0.45%
977,500
– –
GTHX
29
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$15.3M 0.44%
+352,607
New +$15.1M
CDTX
30
DELISTED
Cidara Therapeutics
CDTX
$11.9M 0.34%
114,764
– –
NVAX icon
31
Novavax
NVAX
$1.31B
$11.2M 0.32%
416,500
– –
ACHN
32
DELISTED
Achillion Pharmaceuticals
ACHN
$3.62M 0.1%
1,279,340
– –
PRTA icon
33
Prothena Corp
PRTA
$450M
– –
-400,000
Closed -$14.7M
AVXS
34
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-402,800
Closed -$49.8M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q2 2018 Portfolio in Review

As of Q2 2018, BB Biotech held 34 positions worth $3.46B, down 4.3% from $3.62B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

BB Biotech deployed $105M of net new capital in Q2 2018, opening 4 new positions and adding to 12 existing holdings. Its largest new stake was Nektar Therapeutics: 35,000 shares worth $25.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $29.4M trimmed.

  • BB Biotech's largest Q2 2018 buy was Nektar Therapeutics: 35,000 shares worth $25.6M.
  • BB Biotech added most to Esperion Therapeutics in Q2 2018, an estimated $38.9M increase.
  • BB Biotech's biggest Q2 2018 reduction was Agios Pharmaceuticals, cutting an estimated $29.4M.
  • BB Biotech fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $49.8M.
  • BB Biotech's ten largest holdings make up 67% of its $3.46B portfolio in Q2 2018.
  • BB Biotech opened 4 new positions and closed 2 in Q2 2018.
  • BB Biotech's portfolio value fell 4.3% quarter-over-quarter to $3.46B.

Based on BB Biotech's 13F filing for Q2 2018, filed 9 Aug 2018.